Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | NTSR1 | P30989 | 11/20 | 0.60 |
| ▸ | NTSR2 | O95665 | 9/20 | 0.60 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612065 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611692 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611524 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611985 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29387174 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611528 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29612082 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611824 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29612137 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29420258 | 0.98 | NTSR1 (0.60) | NPY1RNPY2RNPY4RNPY5RNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806770-B2 | Powder formulation | MONASH UNIVERSITY (AU) | 2020-10-20 | — | — | US | disclosed |
| EP-3438121-B1 | LIQUID PHASE SYNTHESIS METHOD FOR OXYTOCIN USING POLYPEPTIDES | LANZHOU KAIBO PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-20190125824-A1 | POWDER FORMULATION | MONASH UNIVERSITY (AU) | 2019-05-02 | — | — | US | disclosed |
| EP-3438121-A1 | LIQUID PHASE SYNTHESIS METHOD FOR OXYTOCIN USING POLYPEPTIDES | Lanzhou Kaibo Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
| CN-107106641-A | Powder formulation | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806770-B2 | Powder formulation | OXTR, CRH, CRHBP | NPY1R 156/4885NPY2R 61/4885NPY4R 163/4885 |
| US-20190125824-A1 | POWDER FORMULATION | OXTR, CRH, CRHBP | NPY1R 149/4885NPY2R 60/4885NPY4R 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.